AbbVie (ABBV)
(Delayed Data from NYSE)
$194.29 USD
-1.16 (-0.59%)
Updated Oct 4, 2024 03:59 PM ET
After-Market: $193.91 -0.38 (-0.20%) 5:14 PM ET
3-Hold of 5 3
C Value D Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$194.29 USD
-1.16 (-0.59%)
Updated Oct 4, 2024 03:59 PM ET
After-Market: $193.91 -0.38 (-0.20%) 5:14 PM ET
3-Hold of 5 3
C Value D Growth F Momentum D VGM
Zacks News
AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $108.22 in the latest trading session, marking a -0.03% move from the prior day.
What's in Store for Edwards Lifesciences (EW) in Q1 Earnings?
by Zacks Equity Research
Continued strength in the adoption of the TruWave disposable pressure monitoring devices and INSPIRIS RESILIA aortic valve are likely to have driven Edwards Lifesciences' (EW) Q1 revenues.
What Makes AbbVie (ABBV) a New Buy Stock
by Zacks Equity Research
AbbVie (ABBV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
AbbVie (ABBV) is a Top Dividend Stock Right Now: Should You Buy?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
Has AbbVie (ABBV) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (ABBV) Outperforming Other Medical Stocks This Year?
Sanofi (SNY) Acquires Tidal to Aid mRNA-Based Research Platform
by Zacks Equity Research
Sanofi's (SNY) acquisition of Tidal Therapeutics for $160 million is set to aid innovative mRNA-based research platform with applications in oncology, immunology and other diseases.
Pharma Stock Roundup: FDA Decision Delays for PFE, LLY, ABBV, AZN Vaccine Woes
by Kinjel Shah
FDA delays decision on Pfizer (PFE), AbbVie (ABBV) and Lilly's (LLY) filings for JAK inhibitor candidates. AstraZeneca's (AZN) COVID-19 vaccine troubles continue.
The Zacks Analyst Blog Highlights: ServiceNow, AbbVie and Apple
by Zacks Equity Research
The Zacks Analyst Blog Highlights: ServiceNow, AbbVie and Apple
Pfizer (PFE) Dermatitis JAK Inhibitor NDA Review Gets Delayed
by Zacks Equity Research
The FDA extends the review period of Pfizer's (PFE) candidate abrocitinib in atopic dermatitis by three months.
AbbVie (ABBV) Seeks Skyrizi Approval for Psoriatic Arthritis
by Zacks Equity Research
AbbVie (ABBV) files regulatory applications with the FDA and the EMA, seeking approval for a new indication of Skyrizi - psoriatic arthritis.
3 Large-Cap Stocks to Buy and Hold to Start Q2
by Benjamin Rains
Now let's jump into three stocks that investors might want to buy now amid the bullish start to the second quarter...
Lilly's (LLY) Olumiant Dermatitis sNDA Review Gets Delayed
by Zacks Equity Research
The FDA extends the review period of Lilly (LLY)/Incyte's (INCY) label expansion application for Olumiant in atopic dermatitis by three months.
AbbVie's (ABBV) Rinvoq Dermatitis sNDA Review Gets Delayed
by Zacks Equity Research
The FDA extends the review period of AbbVie's (ABBV) label expansion application for Rinvoq in atopic dermatitis by three months.
AbbVie (ABBV) Gains As Market Dips: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $106.73, moving +0.71% from the previous trading session.
This is Why AbbVie (ABBV) is a Great Dividend Stock
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $104.84 in the latest trading session, marking a -1% move from the prior day.
AbbVie (ABBV) Down as FDA Extends Review of Rinvoq sNDA
by Zacks Equity Research
The FDA extends the review period of AbbVie's (ABBV) label expansion application for Rinvoq in active psoriatic arthritis by three months.
Pharma Stock Roundup: J&J, AZN COVID-19 Update, FDA Delays Decision on ABBV's sNDA
by Kinjel Shah
WHO gives EUL to J&J's (JNJ) COVID-19 vaccine. FDA pushes back review on AbbVie's (ABBV) sNDA
Lilly (LLY) Mirikizumab Meets Ulcerative Colitis Study Goal
by Zacks Equity Research
Lilly's (LLY) mirikizumab meets primary endpoint and key secondary endpoints in phase III ulcerative colitis study.
AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $110.26 in the latest trading session, marking a +1.89% move from the prior day.
The Zacks Analyst Blog Highlights: Netflix, Toyota, AbbVie, Merck and Sinopec
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Netflix, Toyota, AbbVie, Merck and Sinopec
Top Stock Reports for Netflix, Toyota & AbbVie
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Netflix (NFLX), Toyota Motor (TM), and AbbVie (ABBV).
Zacks Market Edge Highlights: AbbVie, Innovative Industrial Properties, Weyerhaeuser, Nutrien and Broadcom
by Zacks Equity Research
Zacks Market Edge Highlights: AbbVie, Innovative Industrial Properties, Weyerhaeuser, Nutrien and Broadcom
5 Innovative Companies That Will Pay You Cold Hard Cash
by Tracey Ryniec
Who says you have to own "boring" utilities, insurers and telecoms to get big dividends?
Why AbbVie (ABBV) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.